EpiBiologics Raises $107M for Its Protein-Degrading Cancer Drug

EpiBiologics raises $107 million to develop bispecific antibodies against cancer and immune disorders

Today's biotech news covers what we're expecting at JPM 2026, GLP-1 pills reviving the magic bullet debate, and more.

EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology

SAN MATEO, Calif.--(BUSINESS WIRE)--Jan 8, 2026-

EpiBiologics raises $107M for its protein-degrading cancer drug

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of marketed therapies.

EpiBiologics Closes $107M Series B to Advance Pipeline of Novel ...

EpiBiologics Secures $107 Million in Series B Funding to Develop Targeted Cancer Therapy

EpiBiologics, a biotechnology startup, has secured $107 […] The post EpiBiologics Secures $107 Million in Series B Funding to Develop Targeted Cancer Therapy first appeared on GeneOnline News. The post EpiBiologics Secures $107 Million in Series B Funding to Develop Targeted Cancer Therapy appeared first on GeneOnline News.

Former Genentech leaders’ protein degrader startup nets $107M

EpiBiologics raised $107 million to bring its first experimental protein-destroying antibody into the clinic for lung and head-and-neck cancers. The Bay Area biotech’s Series B round was led by GV — Google’s venture arm — as well ...